MARS® Bar supports CD14+ monocyte isolation directly from leukopak or blood, with data showing up to 99% purity & 80-90% recovery. The workflow is designed to reduce manual labor & increase dendritic or macrophage differentiation.
Let's chat ➡️https://t.co/XvYZ6ciqUy
#CellTherapy
For teams developing dendritic cell vaccines or monocyte-derived therapies, MARS® Bar offers a faster and more controlled starting step that can make the rest of the workflow easier to build.
Discover how: ➡️ https://t.co/svLBCr9LDV
#Monocytes#CellProcessing#ImmunoOncology
From early research to GMP, your monocyte workflow should be built to scale. MARS® Bar supports automated, column-free CD14+ enrichment, flexible protocols, & CD14 reagent options for RUO & GMP-oriented workflows.
Talk to us about your CD14+ workflow➡️https://t.co/aLMaOPdnq9
MARS® Bar simplifies CD14+ monocyte isolation by reducing manual steps and achieving faster access to enriched cells.
A streamlined workflow for dendritic cell vaccines, macrophage research & monocyte-derived therapies.
📄 Learn more: https://t.co/elBMnjBrME
#CellTherapy
Monocyte isolation shouldn’t slow down your cell therapy workflow.
With proprietary Ingenuity™ 50nm magnetic beads & the automated MARS® Bar platform, researchers can isolate CD14+ monocytes from PBMCs with a column-free workflow
Discover Now:https://t.co/qgF6vcRrsc #CellTherapy
MARS® Bar automates CD14+ monocyte isolation directly from fresh leukopaks or whole blood into culture media—streamlining workflows for high-quality downstream dendritic cell differentiation.
Learn more about our monocyte isolation➡️
https://t.co/ctGf0LSGkK
New data: automated, column-free CD14+ monocyte isolation with MARS® Bar directly from leukopak or blood, delivering up to 99% purity and up to 90% recovery.
Learn more: ➡️ https://t.co/ILqau369qg
#Monocytes#DendriticCells#CancerVaccines#CellTherapy
Discover our latest brochure on CD14+ Monocyte Isolation for cancer vaccine development on the MARS® Bar. Explore a streamlined workflow for Leukopak or whole-blood inputs, plus performance data and downstream differentiation results.
Download now! https://t.co/xWjhyS29L7
The Applied Cells team wishes everyone a fun-filled 4th of July weekend! Whether you're staying home, firing up the grill, or hanging out at the beach, we hope you find time to recharge and celebrate America's independence!
In day 2, CAR-T cells are ready for harvest directly into formulation buffer—no extra purification or buffer exchange required. It's all done in a single step!
Discover our full day 2 GoFast™ process here: https://t.co/38ToNumVoa
#celltherapy#cellandgenetherapy
Following Day 0 isolation & 24 hours activation, T cells are prepared for transduction. Continuing into Day 1, QC revealed >75% activation with our Ingenuity™ CD3/CD28 reagents.
Discover our full GoFast™ process here: https://t.co/A2Nfvu7mQK
#celltherapy#cellandgenetherapy
🚀 Revolutionize Your CAR-T Manufacturing in 3 DAYS in under $10k with our “Go Fast” Process 🚀
Discover our full GoFast™ process on our Linkedin: https://t.co/onLaEAR0tR
Ready to GoFast™?: https://t.co/MtvfQPwH5h
#celltherapy#healthcareinnovation
In our latest blog, we discuss the emerging solution of Point-of-Care manufacturing that helps bring therapies closer to patients.
✅ Shorter treatment timelines
✅ Personalization based on patient needs
✅ Improved cell quality
Read our full blog here ➡️ https://t.co/vCOrHXMTDt
Join Applied Cells at #ASGCT2026 at 𝗣𝗼𝘀𝘁𝗲𝗿 #𝟮𝟯𝟳𝟮, presented by Yuchen Zhou, CEO & Founder, featuring new data on a rapid GoFast™ BCMA/CD19 dual-targeting CAR-T approach for patients with severe, refractory myasthenia gravis.
See Full Details: https://t.co/o56sD1tng2
Join Applied Cells at #ASGCT2026 at 𝗣𝗼𝘀𝘁𝗲𝗿 #𝟮𝟯𝟳𝟮, presented by Yuchen Zhou, CEO & Founder, featuring new data on a rapid GoFast™ BCMA/CD19 dual-targeting CAR-T approach for patients with severe, refractory myasthenia gravis.
See Full Details: https://t.co/kGp2lutTv6
It's #ASGCT2026 week, and we have poster presentations tomorrow AND Wednesday that you won't want to miss!
➡️ 𝗣𝗼𝘀𝘁𝗲𝗿 #𝟭𝟭𝟵𝟳 | 05/12/2026 |5:00 PM–6 PM
➡️ 𝗣𝗼𝘀𝘁𝗲𝗿 #𝟮𝟯𝟳𝟮 | 05/13/2026 | 5:00 PM–6:30 PM
See Full Details: https://t.co/qSA6xXgUVw
#CART#CellTherapy
We’ve been awarded U.S. Patent No. 12,595,460 B2 covering key methods and instrumentation for CAR-T cell production that support our GoFast™ manufacturing approach.
Read the full announcement here: https://t.co/crO8RvJDVg
#CellTherapy#CART#AdvancedTherapies#Innovation